Biomea Fusion announced the acceptance of three abstracts presenting new clinical data from the ongoing escalation portion of its COVALENT-111 trial, evaluating BMF-219 as a potential treatment for people with type 2 diabetes, at the 17th International Conference on Advanced Technologies & Treatments for Diabetes, ATTD, taking place in Florence, Italy, 6-9 March 2024. This new clinical data from all dosing cohorts initiated to date from the escalation portion of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD. These abstracts further validate the mechanism of action of covalently inhibiting menin in people with type 2 diabetes to potentially provide long-term improvement in glycemic control through beta cell regeneration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMEA:
- Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
- Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control” Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
- Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- Biomea Fusion announces two poster presentations at ASH meeting 2023
- Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
Questions or Comments about the article? Write to editor@tipranks.com